HCL Technologies reported a 0.5% sequential revenue decline for Q1FY27, performing better than expected. Despite record TCV bookings of $2.4 billion, the company maintained a cautious 1-4% growth forecast for FY27. Investors reacted to concerns over AI-related pricing pressure and reduced discretionary spending, leading to a 4.5% drop in the company's share price.
HCL Technologies announced its financial results for the quarter ending June 2026, revealing a mixed performance that balanced strong deal wins against ongoing growth concerns. The company reported a 0.5% sequential revenue decline in constant currency, a result that outperformed analyst predictions of a 1% drop. Despite this, investors focused on the company's cautious outlook, sending the stock down by 4.5% during Tuesday's trading session.
Record Bookings Amid Cautious Guidance
A highlight of the quarter was the company's success in securing new business. HCL Tech recorded net new total contract value (TCV) bookings of $2.4 billion, excluding a recently announced $1.14 billion mega deal. This is the highest level of bookings for a first quarter in the company's history and exceeds its recent four-quarter average of $2.2 billion. Even with this strong pipeline, the management reaffirmed a conservative revenue growth guidance of 1-4% for FY27. This caution stems from expectations of continued pressure from artificial intelligence pricing and specific challenges within certain client accounts.
Segment Performance and Sector Pressures
Performance varied across the company’s business segments. While the IT services business remained flat, the engineering research and development (ER&D) segment saw a 3.7% decline. This drop was largely due to reduced discretionary spending from two major telecom clients in the United States, a trend that has been impacting the sector for several quarters. In contrast, the software products segment provided a boost with 2.2% sequential growth.
Vertical performance also showed distinct trends. The banking, financial services, and insurance (BFSI) sector remained a bright spot, as the company gained more business through AI-driven data and analytics projects. However, the life sciences and healthcare vertical faced pressure as prior regulatory work finished and the US healthcare market remained subdued.
Margin Stability and Future Outlook
On the profitability front, EBIT margins showed improvement compared to the previous quarter. This was helped by lower restructuring costs and favorable foreign exchange movements, though these were partially balanced by seasonal productivity patterns. The company has reaffirmed its EBIT margin guidance of 17.5-18.5% for the full fiscal year.
Analysts hold differing views on the company's path forward. Some research firms highlight that while client-specific issues in the telecom space have tempered growth expectations for FY27, the company's solid deal pipeline and growth in AI-led transformation programs could lead to a better performance in FY28. Others remain cautious, noting that current market valuations may already account for expected gains. Moving forward, investors will be closely tracking the company's ability to convert its record TCV bookings into actual revenue while managing pricing pressure in an increasingly AI-focused market environment.